Nanobiotix spins out Curadigm
Cancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
Double win for Novartis
It was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only treatment developed specifically for patients with a PIK3CA mutation in HR+/HER2-advanced breast cancer.
Most expensive gene therapy globally approved
The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.
Healthy figures from Spain
At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.
Chiesi acquires ex-US Raxone marketing rights
Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (44m) in cash plus sales milestones.
Evotec acquires CDMO Just Biotherapeutics in US$90m deal
Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m.
AI improves protein manufacture
Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.
DNA Script raises US$38.5m in Series B round
In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.
Dutch-Italian team improves retinal gene therapy
Researchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.
Mobidiag secures 25m loan from EIB
Molecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.